INNATE PHARMA EUR0.05 (IPHYF) Rating Increased to Buy at Zacks Investment Research
INNATE PHARMA EUR0.05 (NASDAQ:IPHYF) was upgraded by Zacks Investment Research from a “hold” rating to a “buy” rating in a report issued on Tuesday. The firm currently has a $13.00 price objective on the stock. Zacks Investment Research’s price target suggests a potential upside of 11.21% from the stock’s previous close.
According to Zacks, “Innate Pharma S.A. is a biopharmaceutical company. It develops drugs for treatment of cancer and inflammatory diseases. The company specializes in the development of first-in-class therapeutic antibodies targeting receptors and pathways controlling the activation of the innate immune system. Innate Pharma S.A. is headquartered in Marseilles, France. “
Separately, Leerink Swann reissued a “buy” rating on shares of INNATE PHARMA EUR0.05 in a research report on Wednesday, August 17th.
INNATE PHARMA EUR0.05 (NASDAQ:IPHYF) traded down 1.68% during midday trading on Tuesday, hitting $11.69. 4,750 shares of the stock were exchanged. The firm’s 50 day moving average price is $12.19 and its 200 day moving average price is $12.76. The company’s market cap is $629.82 million. INNATE PHARMA EUR0.05 has a 12 month low of $10.36 and a 12 month high of $16.08.
Receive News & Stock Ratings for INNATE PHARMA EUR0.05 Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for INNATE PHARMA EUR0.05 and related stocks with our FREE daily email newsletter.